Samjin Pharmaceutical revealed its ambitions and clinical results for the antithrombotic drug ‘Flaris Tablets’.
Samjin Pharmaceutical held the ‘HOST’ symposium to commemorate the 17th anniversary of the launch of the antithrombotic drug ‘Platless’ and to share the latest findings on clinical studies of ‘Clopidogrel’ at the Grand Hyatt Seoul in Yongsan-gu, Seoul from August 24th to 25th.
HOST stands for ‘Harmonizing cardiovascular treatment.’ The moderator was Professor Kim Hyo-soo of the Department of Cardiology at Seoul National University Hospital. About 100 cardiology specialists and private practitioners from around the country attended.
The first lecture was given by Professor Kang Ji-hoon of Seoul National University Hospital on the topic of ‘Long-term maintenance therapy for patients receiving coronary artery stent therapy’. Then, Professor Han Jeong-gyu of Seoul National University Hospital gave a lecture on the ‘HOST-PREVENTION’ study. Professor Kim Hyo-soo gave a general comment during the Q&A session after the lecture, saying, “The era of ‘Clopidogrel’ will come in the primary prevention of coronary artery disease.”
Clopidogrel is an antiplatelet drug used to reduce the risk of cardiovascular disease and stroke in high-risk groups.
Samjin Pharmaceutical launched the antithrombotic drug ‘Flatris Tablet’ in January 2007. Flatris Tablet is a ‘Clopidogrel Bisulfate’ formulation and is currently prescribed as a monotherapy or combination therapy (two-drug or three-drug therapy) for cardiovascular, cerebrovascular, and peripheral arterial diseases.
Two years after launching Platless, Samjin Pharmaceutical succeeded in independently synthesizing the raw material for ‘spherical particle (fine bead-shaped) clopidogrel bisulfate’ and obtained manufacturing and synthesis approval from the Ministry of Food and Drug Safety.
Choi Ji-hyun, CEO of Samjin Pharmaceutical, said, “Samjin Pharmaceutical’s ‘spherical particle-type clopidogrel bisulfate’ synthesis technology is so difficult that only one or two companies in the world possess it,” and added, “We will continue to do our best to become a game changer in the global market through ongoing quality management.”
Reporter Ji Hee-soo [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-09-10 22:08:27